Abstract: The present disclosure describes an apparatus comprising a first set of inlet ports to connect with a vehicle charging station, the first set of inlet ports configured to receive first power from a vehicle charging station; a second set of inlet ports to connect with an external power source, the second set of inlet ports configured to receive second power from the external power source; a first set of outlet ports to supply the first power from the vehicle charging station to a first vehicle in a first configuration and the second power from the external power source to the first vehicle in a second configuration; and a second set of outlet ports to direct the first power from the vehicle charging station to a second apparatus in the second configuration, wherein the second apparatus is configured to supply the first power to a second vehicle.

Abstract: The present disclosure describes a connector box, comprising a vehicle inlet port configured to receive a vehicle connector configured to connect to a direct current (DC) or alternating current (AC) vehicle charging station; a locking mechanism configured to secure the vehicle connector within the vehicle inlet port, wherein the locking mechanism is configured to be activated upon insertion of the vehicle connector into the vehicle inlet port and remain activated until deactivation by an authorized user; and an outlet port configured to supply electrical power received via the vehicle inlet port and to an apparatus, the apparatus configured to supply the electrical power from the outlet port to a vehicle connected to the apparatus in a vehicle charging session.

Abstract: The present invention relates to a compound of Formula I, Li(ox)]2[MlmM2nM3k(OH)pFq; wherein M1, M2 and M3 are metals; and X is a halogen chosen from F, Cl and Br; and m, n and k are, independently, a number between 0 and 5, the sum of m, n and k is 5; p and q are, independently, a number between 0 and 8, and the sum of p and q is 8; and to uses thereof and methods of synthesis thereof.

Abstract: The present invention provides an inductor device comprising one or more interconnected columns of conductive material embedded in a supporting structure, wherein the one or more columns comprise an input terminal and an output terminal; and wherein each column is surrounded by a first magnetic layer.

Abstract: An SOP for connection to a first feeder in an electricity distribution network, the SOP being configured to, when a feeder connected to the SOP is faulty, apply a diagnostic voltage to the feeder and make current and voltage measurements at the connection of the SOP to the feeder while the diagnostic voltage is being applied.

Abstract: A broadband power amplifier circuit is disclosed for providing load modulation, and includes an active element for receiving an impedance matched signal and for amplifying the impedance matched signal to supply an amplified signal, and an output matching network having a load impedance and coupled to the active element for receiving the amplified signal, the output matching network matches the load impedance to an optimum load impedance of the active element.

Abstract: There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Abstract: One aspect of the invention relates to a nucleic acid agent targeting a long non-coding RNA target selected from ENSG00000253616 (CHiLL1; SEQ ID NO 001) and ENSG00000272808 (CHiLL2; SEQ ID NO 002) for use in treatment or prevention of recurrence of non-small-cell lung cancer. In another aspect, the invention relates to a pharmaceutical composition comprising a first nucleic acid agent targeting CHiLL1 and a second nucleic acid agent targeting CHiLL2. Particular embodiments provide for the agents and compositions provided in treatment of cancers characterized by KRAS activating mutations, and/or drug resistance. Other particular embodiments provide their combination with platinum anticancer drugs.

Abstract: A method of determining oxygen concentration, metabolic activity, and/or the effects of a test substance on the metabolic activity of a live cell sample by photoluminescence quenching technique employing a photoluminescent probe that self-loads sans any loading reagent into the cells of the cell sample. The probe comprises a plurality of polymeric particles each comprising an amphiphilic cationic polymer matrix having a hydrophobic core and a hydrophilic positively charged surface provided by quaternary amino groups, and a hydrophobic oxygen-sensitive photoluminescent dye embedded in the hydrophobic core.

Abstract: The present disclosure relates to a system, generator and method for generating nanobubbles or nanodroplets and treating a multi-component mixture, and in particular for treating biogas and wastewater. The method comprises using nanobubbles of a gas component, and wastewater, to form hydrates in a treatment vessel; removing residual dirt from the treatment vessel and melting the hydrates to facilitate release of clean water.

Abstract: The invention broadly provides an implantable medical device comprising a liquid rope coil scaffold. The implant may consist essentially of the scaffold, where the scaffold is the implant and pores in the scaffold may incorporates one or more agents (i.e. drugs, growth factors), or the scaffold may comprise only part of the medical device, for example an implant that is partly or fully covered with a layer of the scaffold. The porosity of the scaffold may be tailored to suit the application, for example a porosity that is tailored to hold and release drug or biological molecules in vivo, a porosity to provide a surface roughness that is conducive to promotion of in-vivo bio-integration (for example vascularisation) or prevention of fibrosis, or a porosity that provides structural strength. The scaffold may be essentially tubular, or may be provided as a planar structure, or may be any shape and can be used to coat, fully or partially any shape or size of medical implant.

Abstract: Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation.

Abstract: The invention relates to a method of visualising a peripheral nerve, the method comprising contacting the nerve with a 5-aminolevulinate or a derivative thereof.

Abstract: The present invention relates to a system for measurement of peripheral aberration of the human eye. The system is characterized by a specially designed multifaced mirror having its each face distributed along an elliptical contour. The normal to any point on the elliptical contour bisects an angle formed by the point and the line connecting the two focal points of the elliptical contour. The length of the multifaced mirror is equal to the length of a line segment formed between the intersections of a plurality of tangents drawn at each intersection of the elliptical contour and a plurality of rays. The plurality of rays extends from a focal point at the centre of the entrance pupil to a plurality of other focal points at the centre of the entrance pupil. Each ray has a predetermined difference in gradient with respect to each other adjacent ray.

Abstract: The present invention provides an in vitro method, and in vitro assay, for staging, classification, screening, monitoring, stratification, selecting treatment for, ascertaining whether treatment is working in, and/or prognostication of cancer in a subject comprising determining allelic imbalance and copy number of target gene-regions in tumor DNA from a subject as set out in the application. The present invention also provides a set of oligonucleotide probes and kits for use in the method, and assay, of the present invention.

Abstract: An imaging apparatus for imaging a sample (7) comprises an array of electronically addressable pixels (6) wherein each pixel is arranged to support a surface plasmon resonance therein to generate an evanescent electromagnetic field. This field extends transversely from the pixel so as to be salient from the array at a first side of the array for illuminating the sample at said first side. A light source (15) is arranged to illuminate the array with excitation light therewith to generate said surface plasmon resonance. An optical detector (12A, 12B, 12C) is arranged at a second side of the array which is opposite to said first side of the array for detecting optical radiation returned from the array in response to illumination of the array by said excitation light. A processing unit (4) is arranged to associate the detected optical radiation with the address of the pixel or pixels within the array at which the surface plasmon resonance was generated.

Abstract: The present disclosure relates to a new anti-cancer peptide; a vector encoding same; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said anti-cancer peptide; use of said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine to treat cancer; a method of treating cancer using said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine; and a combination therapeutic for the treatment of cancer comprising said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine.

Abstract: A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.

Abstract: The present disclosure relates to a phase-locked loop (PLL) based on a charge-sharing locking technique, capable of both fractional-N and integer-N operation. The PLL comprises a voltage pre-setting stage; an oscillator: a shared capacitive load; and a switching network configured for selectively connecting the voltage pre-setting stage to the shared capacitive load during a voltage pre-setting stage for applying an expectant voltage to the capacitive load. The switching network is being further configured for selectively connecting the capacitive load to the oscillator during a charge-sharing locking stage for correcting a phase error in response to a difference between the expected voltage of the capacitor and the voltage of the oscillator. Frequency-tracking and waveform-learning stages are also provided for maintaining PVT (process, voltage, temperature) robustness and for suppressing fractional-N spur, respectively.

Abstract: Disclosed is a video summarisation method that includes converting an input video file to a video transcript using speech recognition, segmenting the video transcript into a plurality of paragraphs using a transformer based model, performing relevance ranking of the plurality of paragraphs by assigning a paragraph importance score to each paragraph, based on relevance of each paragraph to an overall content of the video transcript, creating a plurality of candidate summaries from the plurality of paragraphs, each candidate summary comprising two or more paragraphs, performing coherence reranking of the plurality of candidate summaries based on a combination of coherence and relevance of each candidate summary, and selecting a summary based on the coherence reranking.